---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-049604"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:24:17.847893+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95

## Summary
- Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.
- CTIM-76 Phase 1: 12 patients; RECIST response observed from Cohort 3; no CRS>Grade1, no DLT.
- CT-95 Phase 1: 6 patients; approaching target dose with Cohort 4; no CRS>Grade2.
- CT-202 (Nectin-4 x CD3) preclinical; expects regulatory filing for first-in-human trial in Q2 2026.
- Anticipates updated CTIM-76 Phase 1a data and Phase 1b dose selection in Q2 2026; CT-95 data mid-2026.

## SEC filing metadata
- accession: 0001628280-25-049604
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828025049604/0001628280-25-049604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828025049604/cntx-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-049604
- JSON: https://secwatch.observer/filing/0001628280-25-049604.json
- Plain text: https://secwatch.observer/filing/0001628280-25-049604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.